G G Zhanel1, A E Simor, L Vercaigne, L Mandell. 1. Departments of Medicine and Microbiology, Health Sciences Centre and Faculties of Pharmacy and Medicine, University of Manitoba;
Abstract
OBJECTIVE: To compare and contrast imipenem and meropenem in terms of in vitro activity, pharmacokinetics, clinical efficacy and adverse effects. DATA SELECTION: MEDLINE search from 1975 to 1997 and follow-up of references. DATA EXTRACTION: Clinical trials comparing imipenem with meropenem, or either imipenem or meropenem with standard therapy in the treatment of serious infections were selected. DATA SYNTHESIS: Imipenem, the first carbapenem, was first marketed in 1987; meropenem was introduced to the market in 1996. In general, imipenem is more active against Gram-positive cocci while meropenem is more active against Gram-negative bacilli. The agents display similar pharmacokinetics. Clinical studies in patients with serious infections (intra-abdominal infection, respiratory infection, septicemia, febrile neutropenia) report similar bacteriological and clinical cure rates with imipenem and meropenem. Meropenem is approved for the treatment of bacterial meningitis, whereas imipenem is not. Adverse effects are similar. CONCLUSIONS: Current literature supports the use of imipenem at a dose of 500 mg every 6 h and meropenem at 1 g every 8 h for the treatment of severe infections. For the treatment of serious infections, imipenem (500 mg every 6 h or 2 g/day [$98/day]) is more economical than meropenem (1 g every 8 h or 3 g/day [$142/day]) based on acquisition cost.
OBJECTIVE: To compare and contrast imipenem and meropenem in terms of in vitro activity, pharmacokinetics, clinical efficacy and adverse effects. DATA SELECTION: MEDLINE search from 1975 to 1997 and follow-up of references. DATA EXTRACTION: Clinical trials comparing imipenem with meropenem, or either imipenem or meropenem with standard therapy in the treatment of serious infections were selected. DATA SYNTHESIS: Imipenem, the first carbapenem, was first marketed in 1987; meropenem was introduced to the market in 1996. In general, imipenem is more active against Gram-positive cocci while meropenem is more active against Gram-negative bacilli. The agents display similar pharmacokinetics. Clinical studies in patients with serious infections (intra-abdominal infection, respiratory infection, septicemia, febrile neutropenia) report similar bacteriological and clinical cure rates with imipenem and meropenem. Meropenem is approved for the treatment of bacterial meningitis, whereas imipenem is not. Adverse effects are similar. CONCLUSIONS: Current literature supports the use of imipenem at a dose of 500 mg every 6 h and meropenem at 1 g every 8 h for the treatment of severe infections. For the treatment of serious infections, imipenem (500 mg every 6 h or 2 g/day [$98/day]) is more economical than meropenem (1 g every 8 h or 3 g/day [$142/day]) based on acquisition cost.
Authors: J G Guerra; E Casalino; J C Palomino; E Barboza; M del Castillo; M Gonzalez del Riego; V Huapaya; E Antúnez de Mayolo Journal: Rev Infect Dis Date: 1985 Jul-Aug
Authors: J Niinikoski; T Havia; E Alhava; M Pääkkönen; P Miettinen; E Kivilaakso; R Haapiainen; M Matikainen; S Laitinen Journal: Surg Gynecol Obstet Date: 1993-03
Authors: A M Lovering; C J Vickery; D S Watkin; D Leaper; C M McMullin; L O White; D S Reeves; A P MacGowan Journal: J Antimicrob Chemother Date: 1995-07 Impact factor: 5.790
Authors: Anthony W Chow; Gerald A Evans; Avery B Nathens; Chad G Ball; Glen Hansen; Godfrey Km Harding; Andrew W Kirkpatrick; Karl Weiss; George G Zhanel Journal: Can J Infect Dis Med Microbiol Date: 2010 Impact factor: 2.471
Authors: Andrea Sass; Annelien Everaert; Heleen Van Acker; Freija Van den Driessche; Tom Coenye Journal: Antimicrob Agents Chemother Date: 2018-04-26 Impact factor: 5.191
Authors: George G Zhanel; Marianna Pozdirca; Alyssa R Golden; Courtney K Lawrence; Sheryl Zelenitsky; Liam Berry; Frank Schweizer; Denice Bay; Heather Adam; Michael A Zhanel; Philippe Lagacé-Wiens; Andrew Walkty; Neal Irfan; Kurt Naber; Joseph P Lynch; James A Karlowsky Journal: Drugs Date: 2022-03-16 Impact factor: 9.546
Authors: George G Zhanel; Ryan Wiebe; Leanne Dilay; Kristjan Thomson; Ethan Rubinstein; Daryl J Hoban; Ayman M Noreddin; James A Karlowsky Journal: Drugs Date: 2007 Impact factor: 9.546
Authors: Antonello Di Paolo; Giovanni Gori; Carlo Tascini; Romano Danesi; Mario Del Tacca Journal: Clin Pharmacokinet Date: 2013-07 Impact factor: 6.447
Authors: Coleman Rotstein; Gerald Evans; Abraham Born; Ronald Grossman; R Bruce Light; Sheldon Magder; Barrie McTaggart; Karl Weiss; George G Zhanel Journal: Can J Infect Dis Med Microbiol Date: 2008-01 Impact factor: 2.471